Published in Hum Brain Mapp on December 01, 2009
Involvement of the human pedunculopontine nucleus region in voluntary movements. Neurology (2010) 1.60
Combined pedunculopontine-subthalamic stimulation in Parkinson disease. Neurology (2012) 1.45
Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism. Brain (2012) 1.02
Gamma band activity in the reticular activating system. Front Neurol (2012) 0.99
The pedunculopontine nucleus as a target for deep brain stimulation. J Neural Transm (Vienna) (2010) 0.92
Pedunculopontine nucleus area oscillations during stance, stepping and freezing in Parkinson's disease. PLoS One (2013) 0.91
The role of frontostriatal impairment in freezing of gait in Parkinson's disease. Front Syst Neurosci (2013) 0.91
Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study. Mov Disord (2014) 0.89
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. Sleep (2012) 0.89
Using motor imagery to study the neural substrates of dynamic balance. PLoS One (2014) 0.87
The serendipity case of the pedunculopontine nucleus low-frequency brain stimulation: chasing a gait response, finding sleep, and cognition improvement. Front Neurol (2013) 0.86
Pedunculopontine Nucleus Gamma Band Activity-Preconscious Awareness, Waking, and REM Sleep. Front Neurol (2014) 0.85
Cholinergic Mesopontine Signals Govern Locomotion and Reward through Dissociable Midbrain Pathways. Neuron (2016) 0.83
Parkinson's disease and healthy aging: independent and interacting effects on action selection. Hum Brain Mapp (2010) 0.83
Imaging: What can it tell us about parkinsonian gait? Mov Disord (2013) 0.83
Neuroimaging of Freezing of Gait. J Parkinsons Dis (2015) 0.83
Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism. J Neurosci (2015) 0.81
Pedunculopontine nucleus deep brain stimulation in Parkinson's disease. Arch Med Sci (2011) 0.80
Impaired tilt perception in Parkinson's disease: a central vestibular integration failure. PLoS One (2015) 0.80
Motor and Nonmotor Circuitry Activation Induced by Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease: Intraoperative Functional Magnetic Resonance Imaging for Deep Brain Stimulation. Mayo Clin Proc (2015) 0.80
MRI correlates of Parkinson's disease progression: a voxel based morphometry study. Parkinsons Dis (2015) 0.78
PPNa-DBS for gait and balance disorders in Parkinson's disease: a double-blind, randomised study. J Neurol (2015) 0.78
Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Techniques, Side Effects, and Postoperative Imaging. Stereotact Funct Neurosurg (2016) 0.77
Alterations of functional and structural connectivity of freezing of gait in Parkinson's disease. J Neurol (2016) 0.77
Arousal and the control of perception and movement. Curr Trends Neurol (2016) 0.76
Neurophysiological evaluation of the pedunculopontine nucleus in humans. J Neural Transm (Vienna) (2011) 0.76
Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease. Neurosci Bull (2014) 0.75
Functional Connectivity of the Pedunculopontine Nucleus and Surrounding Region in Parkinson's Disease. Cereb Cortex (2016) 0.75
Network effects of deep brain stimulation. J Neurophysiol (2015) 0.75
Lesions causing freezing of gait localize to a cerebellar functional network. Ann Neurol (2017) 0.75
The 10 Hz Frequency: A Fulcrum For Transitional Brain States. Transl Brain Rhythm (2016) 0.75
Arousal, motor control, and parkinson's disease. Transl Neurosci (2015) 0.75
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet (2012) 4.41
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain (2007) 4.13
Mechanisms of deep brain stimulation. Mov Disord (2002) 3.91
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg (2011) 3.30
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet (2013) 3.21
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry (2008) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol (2010) 2.64
A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol (2010) 2.64
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol (2008) 2.46
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry (2011) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res (2008) 2.38
MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol (2013) 2.37
Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry (2010) 2.36
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron (2004) 2.29
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry (2006) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Contralesional repetitive transcranial magnetic stimulation for chronic hemiparesis in subcortical paediatric stroke: a randomised trial. Lancet Neurol (2008) 2.10
The subthalamic nucleus in the context of movement disorders. Brain (2003) 2.10
Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain (2009) 2.05
Highly cited works in neurosurgery. Part II: the citation classics. J Neurosurg (2010) 2.04
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Multimodal imaging of brain reorganization in motor areas of the contralesional hemisphere of well recovered patients after capsular stroke. Brain (2005) 2.03
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
The FM/AM world is shaping the future of deep brain stimulation. Mov Disord (2014) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry (2004) 2.00
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
Bilateral pallidal stimulation for Wilson's disease. Mov Disord (2013) 1.98
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Functional role of the basal ganglia in the planning and execution of actions. Ann Neurol (2006) 1.96
The mechanisms of interhemispheric inhibition in the human motor cortex. J Physiol (2002) 1.92
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord (2006) 1.89
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. Neurosci Lett (2007) 1.86
Constraint-induced therapy in stroke: magnetic-stimulation motor maps and cerebral activation. Neurorehabil Neural Repair (2003) 1.83
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81